Rachel Haurwitz, PhD, co-founder and CEO of Caribou Biosciences. The developer of gene-edited cell therapies co-founded by Nobel laureate Jennifer Doudna, PhD, has raised $115 million in Series C financing—capital that the company plans to use toward developing its CRISPR-based platform, building its pipeline of oncology treatments, and growing its staff and operations. [Caribou Biosciences]
Caribou said it plans to use the capital toward developing its CRISPR-based platform, building its pipeline of oncology treatments, and growing its staff and operations. "This is an exciting moment for genome editing in the cell therapy space,” says CEO and Co-Founder Rachel Haurwitz, PhD . . .
